Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 3
1987 1
1988 5
1989 7
1990 2
1991 4
1992 5
1993 10
1994 5
1995 8
1996 11
1997 10
1998 16
1999 16
2000 23
2001 16
2002 11
2003 31
2004 27
2005 39
2006 52
2007 48
2008 74
2009 74
2010 79
2011 96
2012 94
2013 86
2014 67
2015 74
2016 73
2017 93
2018 77
2019 57
2020 72
2021 80
2022 54
2023 71
2024 51
2025 53
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,502 results

Results by year

Filters applied: . Clear all
Page 1
Association of metabolic syndrome and chronic kidney disease.
Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Scurt FG, et al. Obes Rev. 2024 Jan;25(1):e13649. doi: 10.1111/obr.13649. Epub 2023 Oct 2. Obes Rev. 2024. PMID: 37783465 Review.
Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financial burden on healthcare systems. ...Therefore, the MetS and its individual components are associated with the premature development, accele …
Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financ …
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ, Day C, Bellary S. Bailey CJ, et al. Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3. Curr Diab Rep. 2022. PMID: 35113333 Free PMC article. Review.
RECENT FINDINGS: The SGLT2 inhibitor class of glucose-lowering agents has recently shown beneficial effects to reduce the onset and progression of renal complications in people with and without diabetes. Randomised clinical trials and 'real world' observational studies, mo …
RECENT FINDINGS: The SGLT2 inhibitor class of glucose-lowering agents has recently shown beneficial effects to reduce the onset and progress …
Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk.
Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, Scamporrino A, Musmeci M, Coppolino G, Di Giacomo Barbagallo F, Bosco G, Scicali R, Piro S, Purrello F, Di Pino A. Scilletta S, et al. Biomolecules. 2023 Apr 26;13(5):752. doi: 10.3390/biom13050752. Biomolecules. 2023. PMID: 37238622 Free PMC article. Review.
The classic description of diabetic kidney disease (DKD) involves progressive stages of glomerular hyperfiltration, microalbuminuria, proteinuria, and a decline in the estimated glomerular filtration rate (eGFR), leading to dialysis. ...However, various hypot …
The classic description of diabetic kidney disease (DKD) involves progressive stages of glomerular hyperfiltration, microal …
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Jongs N, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619106 Clinical Trial.
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal …
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic …
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.
Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Mc Causland FR, et al. J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25. J Am Coll Cardiol. 2025. PMID: 39490700 Free article. Clinical Trial.
BACKGROUND: Finerenone has kidney-protective effects in patients with chronic kidney disease with type 2 diabetes, but effects on kidney outcomes in patients with heart failure with and without diabetes and/or chronic kidney dis …
BACKGROUND: Finerenone has kidney-protective effects in patients with chronic kidney disease with type 2 diabete …
Metabolic Syndrome-Related Kidney Injury: A Review and Update.
Lin L, Tan W, Pan X, Tian E, Wu Z, Yang J. Lin L, et al. Front Endocrinol (Lausanne). 2022 Jun 23;13:904001. doi: 10.3389/fendo.2022.904001. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35813613 Free PMC article. Review.
The prevalence of MetS is 20-25%, which is an important risk factor for chronic kidney disease (CKD). MetS causes effects on renal pathophysiology, including glomerular hyperfiltration, RAAS, microalbuminuria, profibrotic factors and podocyte in …
The prevalence of MetS is 20-25%, which is an important risk factor for chronic kidney disease (CKD). MetS causes effec …
Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB, Carpenter A, Dale-Harris I, Dorée C, Estcourt LJ. Roy NB, et al. Cochrane Database Syst Rev. 2023 Aug 4;8(8):CD012380. doi: 10.1002/14651858.CD012380.pub3. Cochrane Database Syst Rev. 2023. PMID: 37539955 Free PMC article.
SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD. Chronic kidney disease (CKD) is defined as abnormalities …
SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a fre …
Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review.
Wu HY, Huang JW, Peng YS, Hung KY, Wu KD, Lai MS, Chien KL. Wu HY, et al. Ren Fail. 2013;35(5):607-14. doi: 10.3109/0886022X.2013.779907. Epub 2013 Mar 28. Ren Fail. 2013. PMID: 23534678 Free article.
BACKGROUND: Microalbuminuria screening is widely used in high-risk populations but seldom used in the general population for detecting chronic kidney disease (CKD). ...However, there was no consensus regarding the cost-effectiveness for microalbumin …
BACKGROUND: Microalbuminuria screening is widely used in high-risk populations but seldom used in the general population for detectin …
Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ. Roy NB, et al. Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD012380. doi: 10.1002/14651858.CD012380.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Aug 4;8:CD012380. doi: 10.1002/14651858.CD012380.pub3. PMID: 28672087 Free PMC article. Updated.
SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD.Chronic kidney disease is defined as abnormalities of k …
SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a fre …
1,502 results